Autolus reported FY25 results in line with expectations with Aucatzyl sales amounting to $ 74.3m, in line with CSS. Management re-iterated FY26 guidance of $ 120-$ 135m in Aucatzyl sales (includes US and UK revenue), which we think is within reach (KBCSe FY26: $ 146.5m) given the strong initial demand and positive real world experience as demonstrated by the ROCCA dataset. In the pipeline, phase 1 data for Aucatzyl in progressive MS by YE26 could provide upside and pique interest from potential ...
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluationAutolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026Independent real-world AUCATZYL® data from ROCCA consortium confirm high...
Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 19 March 2026 to 25 March 2026 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 75 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 19 March 2026 to 25 March 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 57 549 shares. The table belo...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 19 maart 2026 tot 25 maart 2026 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 75 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 19 maart 2026 tot 25 maart 2026, Kepler Cheuvreux in...
We reiterate our BUY rating and increase our target price from €43.0 to €46.0 based on our raised estimates following the very strong FY25 results. We expect BFIT to raise the guidance at the 1Q26 reporting on 16 April given: (a) the strong membership ingrowth in the first 10 weeks of FY26 and into March while guidance was provided in January, (b) the upside from the delay in the increase in VAT in Belgium and (c) upside we expect from the 24/7 staffless model in France which we expect to be ann...
Geopolitical risk has resurfaced, but the nearterm impact on European listed real estate remains contained. Rising energydriven inflation and rates are driving greater dispersion and sharpening the focus on balancesheet quality, while MIPIM 2026 highlighted a pragmatic investor approach. In this report, we adjust target prices and refresh our top picks, removing CTP and adding Irish Residential REIT. Geopolitics and energy: duration matters more than headlines
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 12 maart 2026 tot 18 maart 2026 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 75 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 12 maart 2026 tot 18 maart 2026, Kepler Cheuvreux in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.